Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by C10H12N2on Mar 02, 2022 6:26am
201 Views
Post# 34473866

RE:RE:$2 Million Cash On Hand Makes This A $1.20 Stock @ Best

RE:RE:$2 Million Cash On Hand Makes This A $1.20 Stock @ BestSubjectively the Mona Lisa is said to be worth $850 Million USD.

A piece of art I personally wouldn't buy at a garage sell.

Objectively, we know AGN stock traded at $2.50 USD.

Hence, with massive dilution in the offing a $1.20 USD is not far a fetched valuation.

They plan to raise $9 Million USD.

At $5 USD per share that's 1,800,000 Million newly issued shares.

Add 1.8 million shares to the current outstanding shares of 1,675,000 Million shares.

Total outstanding shares will soon EZ top 3,500,000 Million outstanding shares.

The book runner will also get its pound of flesh and don't let the warrants ever come into play.

The 52 week low of $2.50 USD held a $4 Million USD market cap.

A stock price of $1.20 with 3.5 Million outstanding shares is a market cap of $4.2 Million USD.

Do you believe history can repeat itself in Biotech Stock Penny World?

I Do.








<< Previous
Bullboard Posts
Next >>